CTI BioPharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2023	FY 2004	FY 2003	FY 2002
Period Ending	Dec '23 Dec 31, 2023	Dec '04 Dec 31, 2004	Dec '03 Dec 31, 2003	Dec '02 Dec 31, 2002
Revenue	-	0.2	0.76	0.41
Revenue Growth (YoY)	-	-74.03%	83.23%	-
Cost of Revenue	-	0.15	0.43	0.28
Gross Profit	-	0.05	0.33	0.14
Selling, General & Admin	0	4.3	0.83	0.59
Research & Development	-	1.78	0.07	-
Operating Expenses	0	6.09	0.9	0.59
Operating Income	-0	-6.04	-0.58	-0.46
Interest Expense	-	-0.06	-0.02	-
Interest & Investment Income	-	0	0	-
Other Non Operating Income (Expenses)	-	-1.24	-	0
EBT Excluding Unusual Items	-0	-7.33	-0.6	-0.46
Merger & Restructuring Charges	-	-1.28	-	-
Pretax Income	-0	-8.61	-0.6	-0.46
Income Tax Expense	-	0	0	0
Net Income	-0	-8.61	-0.6	-0.46
Net Income to Common	-0	-8.61	-0.6	-0.46
Shares Outstanding (Basic)	88	24	15	-
Shares Outstanding (Diluted)	88	24	15	-
Shares Change (YoY)	269.20%	63.30%	-	-
EPS (Basic)	-0.00	-0.36	-0.04	-
EPS (Diluted)	-0.00	-0.36	-0.04	-
Free Cash Flow	-0	-3.99	-0.31	0.02
Free Cash Flow Per Share	-	-0.17	-0.02	-
Gross Margin	-	24.42%	42.88%	33.24%
Operating Margin	-	-3059.73%	-75.70%	-110.10%
Profit Margin	-	-4362.65%	-78.55%	-110.47%
Free Cash Flow Margin	-	-2020.45%	-41.37%	4.99%
EBITDA	-	-5.92	-0.56	-0.45
EBITDA Margin	-	-	-73.46%	-108.32%
D&A For EBITDA	-	0.12	0.02	0.01
EBIT	-0	-6.04	-0.58	-0.46
EBIT Margin	-	-	-75.70%	-110.10%
Revenue as Reported	-	0.2	0.76	-
Advertising Expenses	-	0.01	0.01	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.